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Is a high hematocrit value an independent risk factor
for adverse outcome after coronary artery bypass
grafting?
To the Editor:
We read with great interest the recently published article by
Spiess and colleagues.1 In an observational study of 2202
patients undergoing coronary artery bypass grafting (CABG)
in 24 different centers, they found on multivariate analysis
that the most significant predictor of Q-wave myocardial
infarction was a hematocrit greater than 33% on entry to the
intensive care unit. They also noted that patients with a hema-
tocrit less than 25% had the lowest rates of both Q-wave
myocardial infarction and severe left ventricular dysfunction
and concluded that morbidity after CABG might be decreased
by allowing the hematocrit to be low immediately postopera-
tively. These findings have the potential to make an enormous
clinical and financial impact given the frequency of this oper-
ation world-wide. However, before these results can be accept-
ed as valid, it is essential to know whether any of the patients
included in this study had perioperative administration of apro-
tinin, either as part of a clinical protocol or as part of a con-
current trial. This information is not detailed in the article.
Aprotinin administration has been shown to reduce bleed-
ing and increase postoperative hemoglobin levels after CABG
when compared with placebo.2,3 Its use has been associated in
some studies with increased perioperative myocardial infarc-
tion4,5 and decreased vein graft patency rates,2,5,6 although
these findings are not universal.3,7 Patients who have been
given aprotinin would be expected to have a higher postoper-
ative hematocrit level but may also have been at increased risk
of myocardial infarction as a result of an independent effect of
aprotinin causing a hypercoagulable state.8 Therefore, if any
patients in the study reported by Spiess and associates had
received aprotinin, the multivariate analysis should be repeat-
ed to confirm that a higher hematocrit value was indeed an
independent risk factor for Q-wave myocardial infarction and
severe left ventricular dysfunction.
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Reply to the Editor:
My colleagues and I also believe that this article has the
potential to change the way that cardiac operations are per-
formed and particularly some of the transfusion habits sur-
rounding those operations.
I wish to clarify the issue of aprotinin and other antifibri-
nolytic agents. Our study was conducted as an observational
study in the very early 1990s, before the present day wide-
spread use of aprotinin and antifibrinolytic drugs. Indeed, we
are fortunate that this study was performed before the advent
of the almost universal use of one or another of these agents.
Our data showed that aprotinin was used in fewer than 10
patients in 2202 studied. Epsilon aminocaproic acid and
tranexamic acid were used in fewer than 10% of patients. The
data set did not contain detailed information regarding the
dosage of lysine analog antifibrinolytic agents nor the exact
timing of their use. When we examined this issue very early
in the data analysis, we decided that the numbers were too few
and the data too sketchy to include in the larger outcome
analysis. With fewer than 10 patients receiving aprotinin, no
effect could have been proved from the use of that drug. In our
analysis we did not examine whether or not a patient received
any of the antifibrinolytic agents (yes/no), and prevalence did
not differ between outcome groups.
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